List view / Grid view
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...
In this Imaging In-Depth Focus: Norman Peterson, from MedImmune/AstraZeneca, looks at the practical application of in vivo optical imaging in biotherapeutic biodistribution analyses. Plus, experts from MRC Technology discuss high-content imaging in drug discovery, and Molecular Devices feature in our Q&A...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
A collaboration to investigate the link between epigenetics and respiratory disease and to find new drug treatments involves...
15 June 2016 | By Victoria White, Digital Content Producer
MRCT and AstraZeneca are seeking academics with relevant epigenetics targets to collaborate with them to develop novel treatments for respiratory diseases...
26 April 2016 | By Victoria White, Digital Content Producer
The review will identify promising projects and results which could be suitable for translation into better treatments for Epidermolysis Bullosa...
7 April 2016 | By Victoria White, Digital Content Producer
MRC Technology has appointed Dr Les Hughes and Dr Mike Romanos to the board of trustees, effective 1 March 2016...
6 April 2016 | By Victoria White
The parties created IPS-MRCT Joint Centre for Therapeutic Antibodies in order to combine their expertise in research and development...
21 January 2016 | By Victoria White
MRCT will identify projects with the greatest promise for advancement as investigational therapies and advise the Alzheimer's Association on strategies for moving them forward such that they realise the maximum potential...
The pharmaceutical industry is searching for novel drug targets that could produce the next generation of ‘first-in-class’ therapeutic agents. The challenge for academia is to identify and translate such targets and to provide starting points and confidence in the underlying science. The aim should be to generate evidence that modulation…
24 September 2015 | By Victoria White
Disregulation of MALT1 is associated with some subsets of lymphoma suggesting that MALT1 could be a promising drug target for these types of cancer...
28 July 2015 | By Victoria White
UMG and MRC Technology are to collaborate to develop a novel therapy for neurodegenerative diseases based on antibody targeting amyloid beta peptides 4-x...
22 June 2015 | By Victoria White
The Dementia Consortium is funding a new project to target the immune system in the hunt for new treatments for Alzheimer's disease...
10 June 2015 | By Victoria White
MRC Technology and Peptinnovate are collaborating to assess the therapeutic potential in bone diseases of peptides derived from Mycobacterium tuberculosis...
Academia and pharma have always been uneasy bedfellows. There has in the past been tension between both caused by a range of issues that neither party was willing to try and resolve. However, there is a new impetus to solve these issues as both parties have started to realise that…
From the beginning of time in the drug discovery world, the integration of disciplines has driven the identification of new lead molecules. Chemists, pharmacologists and biologists work together to understand a disease state and how to perturb that state back towards a normal healthy condition. However, in the early days…
